Please contact our sales representative to learn more information about this reagents.
Background
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.